TD Cowen analyst Joseph Thome reiterated a Buy rating on Arrowhead Pharma (NASDAQ: ARWR).The analyst commented: "Redemplo Approved For The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE